Reviewing Conversion Labs (OTCMKTS:CVLB) and Amcor (OTCMKTS:AMCR)

Share on StockTwits

Conversion Labs (OTCMKTS:CVLB) and Amcor (NYSE:AMCR) are both consumer staples companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Institutional & Insider Ownership

26.9% of Amcor shares are held by institutional investors. 31.0% of Conversion Labs shares are held by company insiders. Comparatively, 0.2% of Amcor shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Conversion Labs has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Amcor has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

Dividends

Amcor pays an annual dividend of $0.48 per share and has a dividend yield of 4.8%. Conversion Labs does not pay a dividend. Amcor pays out 78.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Analyst Recommendations

This is a breakdown of recent recommendations for Conversion Labs and Amcor, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Conversion Labs 0 0 0 0 N/A
Amcor 2 0 2 0 2.00

Amcor has a consensus price target of $13.00, suggesting a potential upside of 29.74%. Given Amcor’s higher possible upside, analysts clearly believe Amcor is more favorable than Conversion Labs.

Earnings & Valuation

This table compares Conversion Labs and Amcor’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Conversion Labs $8.32 million 1.07 -$1.24 million N/A N/A
Amcor $9.46 billion 1.72 $430.20 million $0.61 16.43

Amcor has higher revenue and earnings than Conversion Labs.

Profitability

This table compares Conversion Labs and Amcor’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Conversion Labs -27.79% -959.40% -82.56%
Amcor 4.07% 18.16% 6.02%

Summary

Amcor beats Conversion Labs on 10 of the 13 factors compared between the two stocks.

About Conversion Labs

Conversion Labs, Inc., an Internet-based direct response marketing company, licenses, acquires, creates, and sells various products to consumers worldwide. Its products include Shapiro MD, a shampoo, conditioner, and leave-in foamer for thicker fuller hair; iNR Wellness MD, a nutritional supplement for immune support; and PDF Simpli, a PDF conversion software. The company sells its products through technology infrastructure and relationships with agencies, third party marketers, and online advertising platforms, as well as through its Websites inrwellness.com and shapiromd.com. The company was formerly known as Immudyne, Inc. and changed its name to Conversion Labs, Inc. in June 2018. Conversion Labs, Inc. was incorporated in 1987 and is based in New York, New York.

About Amcor

Amcor plc develops, manufactures, and sells various packaging products for food, beverage, pharmaceutical, medical, home and personal care, and other products worldwide. It provides flexible packaging products, specialty cartons, plastic bottles and jars, and capsules and closures. The company is based in Bristol, the United Kingdom.

Receive News & Ratings for Conversion Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conversion Labs and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Tiffany & Co.  Issues Quarterly  Earnings Results
Tiffany & Co. Issues Quarterly Earnings Results
Marathon Petroleum  Raised to Hold at ValuEngine
Marathon Petroleum Raised to Hold at ValuEngine
Zacks Investment Research Downgrades LendingClub  to Hold
Zacks Investment Research Downgrades LendingClub to Hold
Peloton  PT Raised to $38.00
Peloton PT Raised to $38.00
TJX Companies  PT Raised to $69.00
TJX Companies PT Raised to $69.00
CBS  Earns “Buy” Rating from Barrington Research
CBS Earns “Buy” Rating from Barrington Research


© 2006-2019 Ticker Report